Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LMAT 
LeMaitre Vascular Inc (LMAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: LMAT (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $104.78
1 Year Target Price $104.78
| 3 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 14.02% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.17B USD | Price to earnings Ratio 46.74 | 1Y Target Price 104.78 |
Price to earnings Ratio 46.74 | 1Y Target Price 104.78 | ||
Volume (30-day avg) 11 | Beta 0.79 | 52 Weeks Range 71.25 - 109.05 | Updated Date 08/14/2025 |
52 Weeks Range 71.25 - 109.05 | Updated Date 08/14/2025 | ||
Dividends yield (FY) 0.76% | Basic EPS (TTM) 2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 0.5667 | Actual 0.6 |
Profitability
Profit Margin 20.08% | Operating Margin (TTM) 25.13% |
Management Effectiveness
Return on Assets (TTM) 7.28% | Return on Equity (TTM) 13.81% |
Valuation
Trailing PE 46.74 | Forward PE 41.32 | Enterprise Value 2020361218 | Price to Sales(TTM) 9.24 |
Enterprise Value 2020361218 | Price to Sales(TTM) 9.24 | ||
Enterprise Value to Revenue 8.61 | Enterprise Value to EBITDA 27.38 | Shares Outstanding 22637500 | Shares Floating 20797091 |
Shares Outstanding 22637500 | Shares Floating 20797091 | ||
Percent Insiders 8.09 | Percent Institutions 93.14 |
Upturn AI SWOT
LeMaitre Vascular Inc
Company Overview
History and Background
LeMaitre Vascular, Inc. was founded in 1983 by George W. LeMaitre. The company initially focused on developing and marketing vascular grafts. Over time, it expanded its product portfolio through internal development and acquisitions, becoming a provider of specialized vascular devices.
Core Business Areas
- Vascular Devices: Develops, manufactures, and markets medical devices for the treatment of peripheral vascular disease.
Leadership and Structure
As of 2023, George W. LeMaitre serves as Chairman and CEO. The company has a standard organizational structure with departments for R&D, manufacturing, sales, marketing, and finance.
Top Products and Market Share
Key Offerings
- Valvulotomes: Devices used to create valves in veins, for use in procedures such as in-situ saphenous vein bypass. Competitors include Getinge AB (GETI-B.ST).
- Grafts: Synthetic vascular grafts used in bypass surgeries. LeMaitre holds an estimated market share of 10% in small diameter grafts globally. Competitors include W. L. Gore & Associates, Getinge AB (GETI-B.ST), and Medtronic (MDT).
Market Dynamics
Industry Overview
The vascular device market is driven by an aging population, increasing prevalence of peripheral vascular disease, and technological advancements. The market is moderately competitive with several major players.
Positioning
LeMaitre Vascular Inc. focuses on specialized vascular devices, carving a niche in specific areas of vascular surgery. Its competitive advantage lies in its specialized product portfolio and focus on innovation.
Total Addressable Market (TAM)
The global vascular grafts market is projected to reach $4.4 billion by 2028. LeMaitre's current market share positions it for continued growth within this TAM.
Upturn SWOT Analysis
Strengths
- Specialized product portfolio
- Strong brand reputation
- Established distribution network
- Focus on innovation
Weaknesses
- Smaller size compared to major competitors
- Reliance on specific product lines
- Limited geographical presence in some markets
Opportunities
- Expanding into emerging markets
- Developing new and innovative vascular devices
- Acquiring complementary businesses
- Increasing market penetration in existing markets
Threats
- Intense competition from larger players
- Pricing pressures
- Regulatory changes
- Product liability risks
Competitors and Market Share
Key Competitors
- MDT
- GETI-B.ST
- BSX
Competitive Landscape
LeMaitre Vascular Inc. competes with larger medical device companies but differentiates itself through its specialized product portfolio and focus on innovation. The competitive landscape is intense, requiring ongoing investment in R&D and sales & marketing.
Major Acquisitions
Provasc Ltd.
- Year: 2022
- Acquisition Price (USD millions): 21
- Strategic Rationale: Expanded LeMaitre's product portfolio in the arteriovenous access market.
Growth Trajectory and Initiatives
Historical Growth: LeMaitre Vascular Inc. has experienced steady growth in revenue and earnings over the past decade, driven by product innovation and strategic acquisitions.
Future Projections: Analysts project continued growth for LeMaitre Vascular Inc., driven by increasing demand for vascular devices and the company's strong product pipeline.
Recent Initiatives: Recent initiatives include the launch of new vascular grafts and the expansion of the company's sales force in key markets.
Summary
LeMaitre Vascular Inc. is a niche player in the vascular device market with a strong product portfolio and a history of growth. Its specialized focus and innovation are key strengths. Challenges include competition from larger companies and the need to continually invest in R&D and market expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (10-K, 10-Q)
- Analyst reports
- Industry publications
- Company website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data and market share estimates are subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About LeMaitre Vascular Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 2006-10-19 | Chairman & CEO Mr. George W. LeMaitre | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 651 | Website https://www.lemaitre.com |
Full time employees 651 | Website https://www.lemaitre.com | ||
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It also provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular and porcine patches; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.